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Introduction
The Centers for Disease Control and Prevention estimates that 161,000 Americans, most of whom are ethnic minorities and women of child-bearing age, suffer the debilitating consequences of systemic lupus erythematosus (or lupus). Lupus is an autoimmune disease characterized by the rampant production of autoantibodies that drive widespread organ damage 1 . As a result, lupus is the 5 th leading cause of death for African American and Hispanic women between 15 and 24 years of age 2 . There is no cure for lupus, and therapy is limited mostly to immunosuppressive drugs. Amongst numerous side effects, these treatments broadly dampen immune responses, causing impaired wound healing and an increased susceptibility to dangerous infections. There is a growing focus on development of immunomodulatory therapies that more selectively constrain pathogenic autoreactive lymphocytes in patients with lupus, thereby obviating the need for potentially harmful non-selective suppression of the immune system.
Multiple lines of evidence in patients with lupus and in mouse models of lupus-like disease point to dysregulation of follicular helper T cell (TFH) and germinal center (GC) B-cell responses as a key driver of disease pathogenesis [3] [4] [5] . The resulting aberrant GC responses facilitate development of autoantibody-secreting plasmablasts that contribute to harmful inflammation and pathogenic deposition of immune complexes in affected organs, including the kidney 1 . While clinical strategies to deplete TFH are presently lacking, broad depletion of B-cells 6 or neutralization of the B-cell activating factor 7 show promise for ameliorating lupus disease. These results suggest that other immunotherapeutic strategies that target TFH and B cells may be able to effectively alleviate lupus disease.
Our previous work revealed that natural killer (NK) cells exhibit potent immunosuppressive capacity that limits TFH and GC responses resulting from infection or vaccination 8, 9 . This activity involves perforin-dependent lysis of a fraction of activated CD4 T cells by NK cells, resulting in reduced antiviral CD8 T cell and humoral immune responses [8] [9] [10] . Unfortunately, the frequency and function of circulating NK cells is markedly reduced patients with lupus [11] [12] [13] [14] [15] , particularly during disease flares [16] [17] [18] . Likewise, NK-cell frequencies are reduced in mouse models of lupus-like disease, including Fas-mutant lpr mice 19 . Of note, antibodymediated depletion of NK cells in these mice accelerated disease, while adoptive transfer of NK cells delayed disease onset 18 . These data suggest that an inherent or acquired NK-cell numeric and functional deficiency may contribute to the pathogenesis of lupus. Moreover, the reduced NKcell pool in the context of lupus coupled with the potent immunoregulatory function of these cells raises the specter of therapeutically expanding NK cells to alleviate lupus disease.
Several methods currently exist to semi-selectively expand endogenous NK cell populations in vivo [19] [20] [21] [22] . These reagents are often based on the NK-cell stimulating activities of the cytokines interleukin-2 (IL-2) and IL-15 23, 24 . Of note, both IL-2 and IL-15 engage NK cells via IL-2 beta receptor (IL-2R, or CD122), which is also expressed on activated T and NKT cells 25 . Therefore, targeting of IL-2 to IL-2R via daclizumab (anti-IL-2R antibody) or IL-2/anti-IL-2 (clone S4B6) antibody complexes (IL-2C), results in marked expansion of the NK-cell and CD8 T-cell compartments in mice and humans 23, 26 . Daclizumab-mediated expansion of immunoregulatory NK cells in multiple sclerosis patients is linked to clinical lessening of disease 26, 27 , whereas IL-2C treatment reduced disease measures in the MRL/lpr mouse model of lupus 28 . Likewise, lupus-like disease in the B6 × DBA/2 F1 mouse model was alleviated by therapeutic administration of IL-2C 29 . In contrast, pre-treatment with IL-2C prior to disease initiation resulted in worse disease. The potential contributions of both NK cells and CD8 T cells in these disparate models complicates interpretation of any potential clinical benefits of IL-2C in human lupus. Moreover, distinct functional consequences of IL-15-versus IL-2mediated expansion of NK cells in infection models 30 suggest that IL-15 superagonist compounds like N-803 (previously known as ALT-803 31 ) may provoke greater immunoregulatory functions in expanded NK cells.
In the present study, we compare the prophylactic and therapeutic effects of both IL-2C-and N-803induced expansion of NK cells in a putatively CD8 T-cell-independent mouse model of lupus-like disease. In this chronic graft-versus-host disease (cGvHD) model 32, 33 , CD4 T cells from B6I-H2-Ab1 bm12 /KhEgJ (bm12) donor mice undergo alloactivation following transfer into C57BL/6 mice due to three amino acid mismatches between their major histocompatibility complex (MHC) class II I-A b molecules.. The resulting cGvHD provokes numerous immunological manifestations resembling lupus, including robust TFH and GC Bcell responses, elaboration of antinuclear antibodies (ANA), and development of glomerulonephritis. Surprisingly, both IL-2C and N-803 exacerbated disease measures in this mouse model. CD8 T cells, but not NK cells, unexpectedly contributed to enhanced disease. Seronegative individuals. These finding provoke re-evaluation of the paradigm concerning NK-cell subset dynamics in humans.
Materials & Methods

Mice.
C57BL/6 and CD45.1 + (B6.SJL-Ptprc a pec b /BoyJ) breeder pairs and experimental recipient mice were obtained from The Jackson Lab. CD45.1 + B6(C)-H2-Ab1 bm12 /KhEgJ (bm12) mice were a kind gift from Dr. Edith Janssen. Male and female mice between eight and twenty weeks of age were used in experiments. All mice were maintained under specific pathogen-free conditions in accordance with guidelines from the Association for Assessment and Accreditation of Laboratory Animal Care International. Experiments were performed in accordance with ethical guidelines approved by the Institutional Animal Use and Care Committee of Cincinnati Children's Hospital Medical Center.
Bm12 cell transfer and tissue harvest. Spleens were harvested from B6(C)-H2-Ab1 bm12 /KhEgJ (bm12) donor mice and passed through 70 m nylon strainers to obtain single-cell suspensions. Following enumeration using 3% acetic acid with methylene blue (StemCell Technologies), splenocytes were resuspended in phosphatebuffered saline and forty to sixty million cells were injected either intraperitoneally or intravenously (via retro-orbital injection under isoflurane anesthesia) into each recipient C57BL/6 mouse. This range of donor cells falls above the necessary minimum dose of thirty million splenocytes previously determined by our colleagues and elsewhere noted 32 . Although early experiments utilized an intraperitoneal graft injection that is traditional to the disease model, later experiments used intravenous delivery due to an observed enhanced consistency of engraftment that did not significantly affect downstream disease measures (data not shown). Donor and recipient mice were age-matched. Female-derived graft was injected into female or male hosts, or male-derived graft into male hosts (but not male-derived grafts into female hosts so as to avoid Y chromosome-mediated rejection). When necessary, whole blood was obtained via laceration of the tail vein and collected into either EDTA or SST Microtainer tubes (BD Biosciences). Prior to staining for flow cytometry, whole blood from EDTA tubes was subjected to red blood cells lysis via ACK Lysing Buffer (Thermo Fisher). Following euthanasia, mouse spleens were weighed and processed into single-cell suspensions (as above), splenic red blood cells were lysed (as above), and remaining splenocytes were enumerated using either Trypan Blue exclusion or 3% acetic acid with methylene blue prior to staining for flow cytometry. Whole blood was collected through the inferior vena cava and serum was isolated using SST Microtainer tubes.
Targeted cytokine treatment. For each mouse, 1 g of recombinant murine IL-2 (PeproTech) was combined with 10 g anti-mouse IL-2 (clone S4B6; BioXCell) in 200 L Hank's Balanced Salt Solution (HBSS), then incubated overnight at 4°C while mixing. For each control mouse, 1 g of recombinant murine IL-2 was incubated overnight with 10 g rat IgG2a (BioXCell) in 200 L HBSS. As a pre-disease treatment, each mixture was intraperitoneally injected every other day for a total of 3 injections, after which a bm12 splenocyte graft was injected the following day (see above). As a post-disease treatment, injections were administered once daily for three days beginning one month after graft injection 29 .
Experimental mice received 200 g/kg of N-803 (provided via collaboration with Altor Biosciences) in PBS injected subcutaneously, while control mice received a molar equivalent of recombinant human IL-15 (Peprotech) in PBS. As a pre-disease treatment, two injections were administered, once every other day, finishing one day prior to bm12 graft injection. As a post-disease treatment, injections were administered once weekly over the course of 3 months, beginning 1 week after bm12 graft injection (for a total of 11 treatments).
Administration of cell-depleting antibodies. For NK cell, CD8 T cell, or mock depletion, mice were intraperitoneally injected once with either 25 g InVivoMAb anti-mouse NK1.1 (BioXCell, clone PK136), 100 g InVivoMAb anti-mouse CD8α (BioXCell, clone YTS169.4), or 25 g InVivoMAb mouse IgG2a isotype control (BioXCell, clone BE0085) in HBSS, respectively. Antibodies were administered one day prior to the first treatment with either IL-2/αIL-2 complexes, N-803, or their respective controls.
ELISA assays. Mouse serum or plasma was assessed via the IgG (Total) Mouse ELISA Kit (Thermo Fisher), according to the manufacturer's directions, using 96-well Nunc Maxisorp plates (Thermo Fisher) with samples diluted 1:20,000 -1:40,000. Serum or plasma was assessed for ANA using the Mouse ANA Total Ig ELISA Kit (Alpha Diagnostic International), according to the manufacturer's directions, with samples diluted 1:50. Total IgG and ANA ELISA plates were read using a GlowMax Discover Microplate Reader (Promega) on the absorbance setting at 450nm.
Flow cytometry.
Fluorescently-conjugated antibodies used were obtained from either Biolegend, Ebioscience (ThermoFisher), Invitrogen, or BD Biosciences. For surface staining, cells were resuspended at a concentration of 1-2×10 6 /mL in 50-100 µL of cold HBSS containing 5% heat-inactivated FBS (Gibco), 100U/mL penicillin, and 100 µg/mL streptomycin ("FACS buffer"). Fluorescently-conjugated antibodies were each added at the manufacturer's recommended concentration. Cells were incubated at 4°C for 20 minutes, then washed twice with FACS buffer, and either analyzed fresh (same-day) or fixed using 100 µL Cytofix (BD Biosciences) for 20 minutes at 4°C. All fixed cells were washed twice with FACS buffer to remove fixative and kept at 4⁰C in FACS buffer until analysis (1-3 days later). Acquisition of stained cells was performed using a Fortessa or LSRII cytometer (BD Biosciences) with FACSDiva software (BD Biosciences).
Statistical analyses. All flow cytometric analysis was performed using FlowJo v.10 software. Compensation was performed using single-colorstained cells and/or UltraComp eBeads (ThermoFisher), while Zombie dye single-color controls were made using cells pre-heated on a heat block at 70°C for 10 minutes. All electronic gating was performed downstream of a forward scatter area by forward scatter height "singlet" gate. ELISA standard curves were generated using the linear regression function in GraphPad Prism, during which analyte concentrations were interpolated based on OD values, then calculated based on dilution factor. All statistical analysis was performed using GraphPad Prism 7. Normal distribution of data was assessed by Kolmogorov-Smirnov test. Significant differences between two datasets exhibiting normal distribution were assessed by unpaired, two-tailed Student's T-test, while non-normally distributed datasets were compared using Mann Whitney U test. Comparisons among multiple groups made via Brown-Forsythe and Welch ANOVA with Dunnett's T3 multiple comparison testing of group means. Longitudinal data were assessed by Mixed-effect modeling with Geisser-Greenhouse correction.
Results
The bm12 cGvHD model is associated with contraction of the NK-cell compartment. Injection of splenocytes from CD45.1 + bm12 mice (graft) into CD45.2 + C57BL/6 recipient (host) mice results in marked splenomegaly characterized by activation and expansion of graft PD1 + CXCR5 + CD4 + TFH cells, host Fas + GL7 + CD19 + GC B cells, and host CD138 + CD19 + plasmabla sts relative to C57BL/6 receiving a control graft of BoyJ splenocytes (Figure 1A) . Despite the increase in splenocyte count during this cGvHD response, the numbers of host CD3 -NK1.1 + NKp46 + NK cells were 60% reduced (p=0.0002) in the spleen (Figure 1B) . This contraction of the NK-cell compartment is consistent with that observed in other mouse models of lupus-like disease 18 as well as in patients with lupus [11] [12] [13] [14] [15] . In addition to quantitative reductions, host CD3 -NK1.1 + NKp46 + splenic NK cells from bm12-engrafted mice exhibited higher surface expression of CD27 (Tnfrsf7), NKG2A (Klrc1), Tumor necrosis factor-related apoptosisinducing ligand (TRAIL/Tnfsf10), and CD11c (Itgax) than mice injected with a CD45.1 + control graft (Figure 1C) . This phenotype (CD27 + , NKG2A + , TRAIL + ) is consistent with more immature NK cells 34 , while the increased expression of CD11c is characteristic of an atypical, pro-inflammatory NKcell subset observed in patients with lupus and certain mouse models of lupus-like disease [35] [36] [37] . Disease-associated attrition of NK cells can be reversed with targeted cytokine treatment. Injections of IL-2C (IL-2 complexed with S4B6 anti-IL-2 antibody) or the IL-15 superagonist N-803 into C57BL/6 mice results in expansion of the NK-cell and CD8 T-cell compartments, whil e Foxp3 + CD4 + T regulatory cell proportions remained relatively unchanged 38, 39 . To determine if NK-cell attrition in the bm12 model can be averted via cytokinemediated expansion of the NK-cell compartment, we treated C57BL/6 mice with IL-2C three times over a span of six days prior to initiation of disease model. Pre-treatment with IL-2C before injection of bm12 cells resulted in a >6-fold increase in host splenic NK-cell frequencies relative to controltreated (IL-2 and rat IgG2a) mice receiving a bm12 graft (Figure 1B) . Likewise, pre-treatment with N-803 promoted a >5-fold increase in the frequency of host splenic NK cells relative to untreated bm12engrafted mice. Of note, NK-cell frequencies in IL-2C-or N-803-treated mice were >2-fold greater than in control mice given a non-disease inducing graft of CD45.1 + splenocytes (Figure 1B) . Thus, cytokine-mediated expansion of NK cells prior to bm12 cell transfer can prevent or even reverse model-associated attrition of NK cells. IL-2C or N-803 pretreatment transiently exacerbates cGvHD. The diminished number of potentially immunoregulatory 8-10, 26, 40-51 NK cells in the bm12 model of disease (Figure 1B ) may contribute to dysregulated responses of T and B cells leading to autoimmune disease. Accordingly, the marked expansion and maintenance of high number of NK cells after IL-2C pre-treatment should result in diminished measures of cGvHD and lupus-like disease. In contrast to expectations, the number of host GC B cells and plasmablasts in the spleen of IL-2C-treated, bm12-engrafted C57BL/6 mice two weeks after disease initiation was elevated relative to mice treated with IL-2 and non-complexed irrelevant IgG2a (Figure 2A) . Total serum immunoglobulin (IgG) levels were also higher in IL-2C-treated bm12-recipient mice. This enhanced disease measurement was not sustained at three months, when IL-2/S4B6 pre-treated and control-treated mice exhibited similar numbers of both host GC B cells and plasmablasts (Figure 2B) . A comparable titer of antinuclear antibodies (ANA) was also observed in sera of IL-2/S4B6 pre-treated mice relative to controls. Thus, exacerbated cGvHD lupus-like disease at the two-week time point in IL-2/S4B6 or N-803-treated mice was not associated with sustained amplification of lupus-like disease.
Since IL-15-based expansion can more robustly trigger accumulation of NK cells with greater immunoregulatory capacity than is seen with IL-2C- mediated expansion 3 0 , we tested the hypothesis that N-803 pre-treatment would reduce disease measures in the bm12 model. Unfortunately, host plasmablast counts were also elevated in diseased mice pretreated with N-803 relative to control mice treated with molar-equivalent IL-15 (Figure 3A) . There was also a non-statistically significant trend towards increased sera IgG titers and host GC Bcell counts at two weeks in N-803 pre-treated mice. These increases were short-lived, as analysis 3months post-disease initiation revealed similar numbers of GC B cells, plasmablasts and ANA titers in N-803 pre-treated mice relative to control mice (Figure 3B) . Although the near-absence of ANA titers in two of three N-803 treated mice appeared promising, we calculate that more than 170 mice would need to be assessed in each group to achieve 80% power to detect a statistically significant difference with a  of 0.05.
Therapeutic application of IL-2C or N-803 exacerbates lupus-like disease in mice. To assess whether cytokine-mediated expansion of NK cells can alleviate established lupus-like disease, control and bm12-recipient mice were administered daily therapeutic regimens of IL-2C for 3 consecutive days one month after disease initiation. Twomonths after therapy initiation, IL-2C-treated mice exhibited increased host splenic plasmablast counts and elevated sera ANA titers relative to control treated mice (Figure 4) . Non-significant trends for elevations in host GC B-cell counts and total sera IgG expression levels were also observed. Thus, similar to pre-treatment, therapeutic application of IL-2C exacerbates measures of disease in this model.
In a similar set of experiments, weekly N-803 or control IL-15 injections were initiated one week after bm12 splenocyte infusion and continued for eleven weeks. Splenocyte counts gradually increased with time (p=0.003) in this disease model, and were significantly increased (p=0.02) in mice treated with N-803 compared to IL-15-treated control animals (Figure 5A) . The magnitude of the donor (CD45.1+) TFH cell (p=0.05) and host (CD45.2 + ) plasmablast (p=0.08) responses were also increased with N-803 administration relative to control-treated mice (Figure 5A) . By the third month of disease, N-803 treated mice exhibited increased sera ANA titers (p=0.03) and evidence of proteinuria (Figure 5B) . Collectively, these data suggest cytokine-based approaches aimed at expansion of NK cells may exacerbate lupus-like disease.
CD8 T cells, but not NK cells, contribute to N-803mediated enhanced B-cell responses. N-803 treatment of non-diseased C57BL/6 mice induces a 5.5-fold increase in circulating peripheral NK cells on day two (Control: 11.0±0.07% NK cells; N-803: 60.3±1.1% NK cells), which is sustained for at least two weeks after initiation of the bm12 cGvHD model (Figure 1B) . In contrast, NK-cell frequencies were not measurably elevated (p=0.5) at any time point analyzed when N-803 therapy was initiated after bm12 cell infusion (Figure 6A ). Yet, consistent with the capacity of N-803 to stimulate CD8 T cell proliferation, the number of CD8 T cells in the spleen of bm12-infused mice subjected to therapeutic N-803 treatment was consistently elevated (p=0.03) at all time points assessed (Figure 6B) . To evaluate the contribution of CD8 T cells to enhanced disease measures, C57BL/6 mice were depleted of NK cells or CD8 T cells with anti-NK1.1 or anti-CD8 antibodies, respectively. Thereafter, depleted and non-depleted mice were pre-treated with N-803 for one week prior to engraftment of bm12 splenocytes. The number of splenic CD8 T cells were elevated in N-803 treated immune-replete and NK-cell depleted mice relative to controltreated mice and mice depleted of CD8 T cells prior to treatment (Figure 6C) . Importantly, host GC B- cell responses were increased following N-803 pretreatment of bm12-engrafted mice in non-depleted control mice (p=0.002) and in mice depleted of NK cells (p=0.003) prior to N-803 administration (Figure 6C) . However, this increase was ameliorated (p=1.0) by CD8 T-cell depletion prior to N-803 therapy. Thus, an N-803-induced increase in CD8 T-cell frequencies in the bm12 lupus-like GvHD model is associated with enhanced disease measures.
Discussion
The investigation herein sought to determine whether IL-2C or N-803-medaited expansion of NK cells would alleviate lupus-like disease features in the bm12-based cGvHD mouse model. Unexpectedly, both therapeutic and prophylactic administration of these cytokine-based therapeutics at least transiently enhanced disease measures. Through depletion studies, CD8 T cells were implicated in the disease aggravating activity of N-803. These results suggest that activation and expansion of CD8 T cells may be unfavorable in the context of lupus, which is consistent with the correlation between elevated CD8 T-cell frequencies and poor disease prognosis in patients with lupus 52 . Our findings represent pertinent discoveries regarding the dynamics between NK cells, CD8 T cells, and systemic autoimmune disease in mice.
Similar to the paucity of circulating NK cells in patients with lupus and reduced numbers of NK cells in other mouse models of lupus-like disease 11-16, 37, 53, 54 , we observe a marked contraction of the NK-cell compartment in mice subjected to the bm12 cGvHD model. Though the cause of this contraction remains undefined, we find that prophylactic treatment of diseased mice with either IL-2C or N-803 can counteract NK-cell loss and even promote expansion of the NK-cell pool. Coupled with experiments detailing IL-2-based therapeutics in the MRL/lpr and B6 x DBA mouse models 28, 29 , these data support the conclusion that therapeutic expansion of NK cells is possible in the context of lupus-like disease.
Unfortunately, application of IL-2C or N-803 to the bm12 cGvHD model of lupus at least transiently exacerbated disease. In the case of N-803, the expansion of CD8 T cells was implicated in exaggerated bm12-engraftement-induced GC responses. As N-803 can promote secretion of IFN- from CD8 T cells 31, 39, 55, 56 , and IFN- can cause pathologic accumulation of TFH cells and GCs 57-59 , we speculate that excess IFN- production after N-803 or IL-2C therapy may provoke worse disease outcomes. Regardless of the mechanism by which CD8 T cells aggravate disease measures in this model, it is interesting to note that our results contrast with those obtained following therapeutic application of IL-2C to the B6 × DBA/2 F1 cGvHD mouse model of lupus-like disease 29 , in which IL-2C-stimulated CD8 T cells ameliorated disease. This dichotomy is likely explained by the role of additional class I MHC mismatches in the B6 x DBA/2 F1 model that are not present in the bm12 model. In B6 x DBA/2 F1 system, IL-2C enhancement of CD8 T cells would lead to improved rejection of class I-mismatched cells, thereby curtailing the cGvHD response driving lupus-like disease. A similar elimination of pathogenic cells may drive the reduction in disease observed after IL-2C therapy of lupus-like disease in MRL/lpr mice.
While evidence for beneficial functions of NK cells in lupus remains scarce, our data suggest that specific expansion of NK cells (in the context of CD8 T cell depletion) is not necessarily detrimental to disease progression. The potential for increased clinical safety of NK cell-based versus T-cell based immunotherapy strategies has already been established in the context of chimeric antigen receptor cellular therapy of cancer 60 . Since no mouse model of lupus-like disease accurately reflects all of the parameters driving human lupus, these studies collectively suggest that cytokinemediated expansion of effector lymphocytes may still hold promise in the clinic if the dueling roles of NK cells and CD8 T cells in lupus-like disease can be better delineated. The advancement and further testing of NK-cell expansion for autoimmune disease will likely require development of reagents that specifically target NK cells and an improved understanding of the factors driving specific subsets of immunoregulatory NK cells.
Collectively, our data suggests that treatment of lupus with immunotherapeutics that selectively expand endogenous CD8 T and NK cells should be approached with caution and may not achieve the therapeutic effect of similar agents that has been observed in multiple sclerosis. Moreover, the increased risk of hematologic malignancy in patients with lupus 61 may complicate clinical application of N-803 or other antitumor therapeutics with the potential to aggravate autoimmune sequelae in these patients. On the other hand, NK cells are potent antitumor effector cells, and selective expansion of these cells without concurrent autoimmune-exacerbation by T cells may provide clinically valuable anti-leukemic effects even if these NK cells are unable to alleviate underlying elements of lupus-like disease.
